Selventa develops software and licensed products for analyzing healthcare patient and molecular data to support personalized healthcare and early patient stratification. The company partners with pharmaceutical and biotechnology firms to help find optimal treatments for the right patients and optimize development portfolios. Selventa's offerings are powered by the Genstruct Technology Platform and an in-silico Reverse Causal Reasoning approach that translates large-scale data into meaningful, testable molecular mechanisms. It engages in collaborative projects and the strategic development of well-differentiated pharmaceutical portfolios across a variety of disease areas. Founded in 2002 and based in Cambridge, MA, Selventa has participated in more than 60 collaborative projects worldwide and recently raised $5 million in a venture capital financing.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2011